Liquidia Corporation
LQDA
Kedudukan dalam Saham
#4829
Liquidia Corporation operates as a biopharmaceutical enterprise, concentrating... Liquidia Corporation operates as a biopharmaceutical enterprise, concentrating on the development, production, and market introduction of various treatments aimed at fulfilling critical patient requirements throughout the United States. A key asset in its developmental portfolio is YUTREPIA, an innovative inhaled dry powder version of treprostinil, intended for managing pulmonary arterial hypertension. Beyond its pipeline, the company also distributes a generic treprostinil injection within the U.S. market. Founded in 2004, Liquidia Corporation's main office is located in Morrisville, North Carolina.
Harga Saham
$34.35
Disegerakkan terakhir: 2026-10-16
Modal Pasaran
$3.07B
Perubahan (1 hari)
-1.23%
Perubahan (1 tahun)
52.81%
Negara
US
Perdagangan Liquidia Corporation (LQDA)
Kategori
Healthcare
EPS untuk Liquidia Corporation (LQDA)
EPS setakat June 2026 TTM: $1.57
Menurut laporan kewangan terkini dan harga saham Liquidia Corporation, EPS semasa syarikat (TTM) adalah $1.57. Pada akhir tahun 2023, syarikat mempunyai EPS sebanyak $-1.21 peningkatan berbanding EPS tahun 2022 iaitu $-0.67.
Sejarah EPS untuk Liquidia Corporation dari 2016 hingga 2026
EPS pada akhir setiap tahun
| Tahun | EPS | Ubah |
|---|---|---|
| 2026 (TTM) | $1.57 | -194.58% |
| 2024 | $-1.66 | 37.19% |
| 2023 | $-1.21 | 80.60% |
| 2022 | $-0.67 | -4.29% |
| 2021 | $-0.70 | -60.23% |
| 2020 | $-1.76 | -29.88% |
| 2019 | $-2.51 | -66.17% |
| 2018 | $-7.42 | 118.24% |
| 2017 | $-3.40 | 82.80% |
| 2016 | $-1.86 | 0.00% |
EPS untuk syarikat atau pesaing yang serupa
| Syarikat | EPS | Perbezaan EPS | Negara |
|---|---|---|---|
| $2.41 | 53.50% |
US
|
|
| - | - |
SE
|
|
| - | - |
FR
|
|
| - | - |
IT
|
|
| $0.02 | -98.80% |
HK
|
